March 10 (Reuters) - Synairgen Plc SYNG.L
- Additional positive data in lung fibrosis
- Oral administration of one of the compounds significantly inhibited cross-link formation, reduced fibrosis score and improved lung function
- Successful completion of toxicology studies will enable commencement of phase I clinical trials in h2 this year as planned
- Expect to commence phase I clinical trials of LOXL2 inhibitor during second half of 2017
- Expect to hear outcome of Astrazeneca phase II trial of interferon beta during first half of 2017
News: PXS Synairgen announces additional positive data from LOXL2 inhibitor programme
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
-0.001(3.23%) |
Mkt cap ! $38.71M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.2¢ | 3.0¢ | $69.25K | 2.272M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 2610649 | 2.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 416503 | 1 |
View Market Depth
| Last trade - 15.57pm 05/09/2024 (20 minute delay) ? |
| SNT (ASX) Chart |